Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 2, 2018

Eppendorf

Eppendorf is a leading life-science company that develops and sells instruments, consumables, and services for liquid-, sample-, and cell handling.

Eppendorf is a leading life-science company that develops and sells instruments, consumables, and services for liquid-, sample-, and cell handling. Its portfolio includes pipettes and automated pipetting systems, mixers, spectrometers, and DNA amplification equipment, bioreactors, CO2 incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, plates, and disposable bioreactor vessels complement the range of premium products.

Eppendorf
102 Motor Parkway,
Hauppauge, NY 11788
custserv@eppendorf.com
tel. 800.645.3050
Pittcon Booth #: 2319

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.